Table 1.

Characteristics of Participants

	Total (n = 55)	Designated male at birth (n = 26)	Designated female at birth (n = 29)
Age at GnRHa start, mean (range), y	11.5 (9.0–14.5)	11.9 (10.2–14.5)	11.1 (9.0–13.9)
Gender, n (%)
Female	10 (18%)	10 (38%)	0 (0%)
Male	15 (27%)	0 (0%)	15 (52%)
Transgender female	14 (25%)	14 (54%)	0 (0%)
Transgender male	13 (24%)	0 (0%)	13 (45%)
Nonbinary	3 (5%)	2 (8%)	1 (3%)
Race/ethnicity, n (%)
White	34 (62%)	13 (50%)	21 (72%)
Black or African American	2 (4%)	1 (4%)	1 (3%)
Multi-race	5 (9%)	2 (8%)	3 (10%)
Hispanic or Latino	12 (22%)	9 (35%)	3 (10%)
Unknown	2 (4%)	1 (4%)	1 (3%)
Tanner stage at GnRHa start, n (%)
II	34 (62%)	21 (81%)	13 (45%)
III	16 (29%)	3 (12%)	13 (45%)
IV	5 (9%)	2 (8%)	3 (10%)
BMI Z-score, mean (SD)
Baseline visit	0.46 (0.89)	0.56 (0.84)	0.38 (0.94)
12-month visit	0.66 (0.97)	0.68 (1.00)	0.63 (0.95)
FSH, median (IQR), IU/L
Baseline visit	2.3 (1.4–4.3)	1.6 (1.1–2.3)	4.1 (2.3–5.4)
12-month visit	0.8 (0.4–1.6)	0.6 (0.15–1.2)	1.1 (0.7–2.0)
LH, median (IQR), IU/L
Baseline visit	0.8 (0.2–2.2)	0.7 (0.3–1.6)	0.8 (0.1–2.8)
12-month visit	0.3 (0.2–0.7)	0.4 (0.2–1.0)	0.3 (0.2–0.4)
Estradiol, median (IQR), pg/mL
Baseline visit	7.0 (2.5–20.0)	2.0 (2.0–6.0)	12.0 (6.0–23.0)
12-month visit	2.0 (2.0–6.0)	2.0 (2.0–2.0)	2.0 (2.0–6.0)
Testosterone, median (IQR), ng/dL
Baseline visit	12.0 (9.0–30.0)	13.0 (9.5–71.0)	12.0 (4.0–18.0)
12-month visit	8.5 (7.0–12.0)	10.0 (7.5–11.5)	6.0 (3.0–12.0)